| Not Yet Recruiting | ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer NCT06224673 | Laura Huppert, MD, BA | Phase 2 |
| Recruiting | The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patient NCT07341503 | Ohio State University Comprehensive Cancer Center | — |
| Recruiting | 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss NCT07044310 | Mayo Clinic | Phase 2 |
| Recruiting | Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow A NCT06486883 | MedSIR | Phase 2 |
| Recruiting | A Study of Revaree Plus in People With Breast Cancer NCT07042581 | Memorial Sloan Kettering Cancer Center | Phase 4 |
| Recruiting | Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women Wi NCT06534125 | Emory University | N/A |
| Recruiting | Mobile Health for Adherence in Breast Cancer Patients NCT06112613 | ECOG-ACRIN Cancer Research Group | N/A |
| Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Soli NCT06120283 | BeOne Medicines | Phase 1 |
| Recruiting | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclopho NCT06058377 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) NCT06106282 | Mayo Clinic | — |
| Recruiting | Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advan NCT06805812 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Active Not Recruiting | Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study NCT05568472 | SWOG Cancer Research Network | N/A |
| Terminated | A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adhe NCT05488145 | Emory University | N/A |
| Unknown | CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer NCT05870813 | Institut fuer Frauengesundheit | — |
| Active Not Recruiting | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas NCT05565417 | Immunitas Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negati NCT05464810 | Emory University | EARLY_Phase 1 |
| Recruiting | Neoadjuvant Breast Cancer Time Restricted Eating NCT05327608 | Thomas Jefferson University | N/A |
| Withdrawn | Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Ca NCT05244434 | City of Hope Medical Center | N/A |
| Completed | Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer NCT05173103 | University of Milano Bicocca | — |
| Terminated | Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer NCT04720664 | Georgetown University | Phase 2 |
| Withdrawn | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer NCT04498520 | Pamela Munster | Phase 1 |
| Active Not Recruiting | Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiv NCT04379570 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Active Not Recruiting | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy NCT04762979 | Marina N Sharifi | Phase 2 |
| Terminated | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) NCT04726332 | Exelixis | Phase 1 |
| Completed | Elacestrant in Preoperative Setting, a Window of Opportunity Study NCT04797728 | SOLTI Breast Cancer Research Group | EARLY_Phase 1 |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" NCT04314401 | National Cancer Institute (NCI) | — |
| Recruiting | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hor NCT04553770 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study NCT04316117 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Completed | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breas NCT04505826 | Olema Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Terminated | Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer NCT04305236 | University of California, Irvine | Phase 2 |
| Recruiting | Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. NCT04305834 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors NCT03845166 | Exelixis | Phase 1 |
| Unknown | Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulatin NCT05814224 | Centro di Riferimento Oncologico - Aviano | N/A |
| Completed | A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers NCT03251378 | Hutchison Medipharma Limited | Phase 1 |
| Completed | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients NCT02003209 | National Cancer Institute (NCI) | Phase 3 |